Singh, Dave <br/><br/>
Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA.  [electronic resource] 

 -  International journal of chronic obstructive pulmonary disease   
 - 531-546 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1178-2005 
<br/><br/><label>Standard No.: </label>10.2147/COPD.S196383  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Inhalation<br/>Adrenal Cortex Hormones--administration & dosage<br/>Adrenergic beta-2 Receptor Agonists--administration & dosage<br/>Aged<br/>Beclomethasone--administration & dosage<br/>Bronchodilator Agents--administration & dosage<br/>Disease Progression<br/>Drug Combinations<br/>Female<br/>Forced Expiratory Volume<br/>Formoterol Fumarate--administration & dosage<br/>Glycopyrrolate--administration & dosage<br/>Humans<br/>Lung--drug effects<br/>Male<br/>Middle Aged<br/>Muscarinic Antagonists--administration & dosage<br/>Nebulizers and Vaporizers<br/>Pulmonary Disease, Chronic Obstructive--diagnosis<br/>Randomized Controlled Trials as Topic<br/>Surveys and Questionnaires<br/>Time Factors<br/>Treatment Outcome